Dizal Pharma Swings to 3.64B Yuan Profit in First Three Quarters of 2026

The scale of the swing is the story: a single quarter delivered nearly all of the nine-month revenue and more profit than the full period, meaning the result rests on one concentrated revenue event rather than a broadened base. That distinction matters for anyone tracking whether this is a durable commercial inflection or a one-off recognition. The gap between reported and non-recurring profit is narrow, so the headline number is not being flattered by below-the-line items — but how much of the third-quarter surge recurs is the open question.